What is the primary purpose of this agreement between Regeneron and Bayer?

The agreement is for the global development and commercialization of Regeneron's VEGF Trap for the treatment of eye diseases (referred to as VEGF Trap-Eye). Bayer will be responsible for commercialization outside the United States.

What are the financial implications of this deal for Regeneron in the short term?

Regeneron will receive an immediate $75.0 million up-front payment from Bayer. Additionally, the company is eligible to receive up to $110 million in development and regulatory milestones.

How are the development costs for VEGF Trap-Eye being shared?

Development costs are shared, with specific arrangements outlined for 2007, 2008, and beyond. Initially, costs are shared equally up to certain thresholds, with Regeneron taking on sole responsibility for additional expenses before cost-sharing resumes. From 2009 onwards, all expenses are shared equally.

What are Regeneron's rights and responsibilities within the United States?

Within the United States, Regeneron is solely responsible for any future commercialization of the VEGF Trap-Eye and retains exclusive rights to all future profits arising from its sale in the U.S.

REGN 8-K: Material Agreements

Summary

Regeneron Pharmaceuticals, Inc. (REGN) has entered into a significant license and collaboration agreement with Bayer HealthCare LLC on October 17, 2006, to develop and commercialize the VEGF Trap for eye diseases (VEGF Trap-Eye). This deal provides Regeneron with an immediate $75.0 million up-front payment, with further potential for substantial milestone payments up to $245 million ($110 million in development/regulatory milestones and $135 million in sales milestones). The agreement outlines a shared global development plan with specific expense-sharing arrangements that evolve over time, and importantly, Regeneron retains all rights to the VEGF Trap-Eye, including exclusive commercialization and profit rights within the United States.

Key Highlights

1Regeneron enters a global development and commercialization agreement for VEGF Trap-Eye with Bayer HealthCare.
2Regeneron receives an upfront payment of $75.0 million from Bayer.
3Potential for up to $110 million in development and regulatory milestones, including $40 million for Phase 3 initiation.
4Potential for up to $135 million in sales milestones based on achieving specific annual sales targets outside the US.
5Regeneron retains exclusive commercialization rights and all profits from VEGF Trap-Eye within the United States.
6Global development expenses are shared, with evolving cost-sharing structures between Regeneron and Bayer.
7Regeneron retains all rights to VEGF Trap-Eye in the event of termination by Bayer.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Oct 18, 2006)

Summary

Key Highlights

Frequently Asked Questions